Charles River to plug into Eli Lilly’s TuneLab platform to standardize nonclinical testing

Eli Lilly is expanding how teams conduct early-stage drug testing by working with Charles River Laboratories to integrate its nonclinical testing services into Lilly’s TuneLab platform, according to a report published by Hospital Management. The collaboration is aimed at helping make testing protocols more consistent across organizations, a goal that can matter when multiple sites or service providers contribute to the same body of preclinical evidence.

TuneLab is Lilly’s technology platform intended to support drug development with standardized data and processes across parts of the research workflow. In this context, “nonclinical testing” refers to studies conducted before human trials, typically including laboratory and animal studies to assess toxicity, pharmacology, and other biological or safety questions needed to advance candidates. Standardization of those protocols is designed to reduce variability that can complicate interpretation of results and decision-making downstream.

The reported deal points to Charles River taking on a role as a testing provider within the TuneLab ecosystem. By bringing external testing work into a common platform framework, Lilly is effectively trying to align how studies are planned, executed, and documented, so that data generated by different organizations can be compared and reused more efficiently.

While the report describes the collaboration’s purpose, it does not lay out the specific study types to be integrated first, the scope of services, or whether the arrangement is limited to a particular therapeutic area, stage, or geography. It also does not provide commercial terms such as duration, pricing structure, or capacity commitments.

For Charles River, partnerships that embed its laboratory capabilities into a customer’s workflow can be a way to deepen engagement beyond stand-alone contracts. For Lilly, integrating a major contract research organization into TuneLab could also help scale nonclinical work while maintaining consistent protocols, at least for the portions that flow through the platform.

The announcement comes as biopharma companies increasingly invest in data and workflow tools to improve reproducibility in preclinical research. In practice, standardization is a recurring challenge: protocols can differ by sponsor, site, and service provider, and those differences can introduce noise into the data used to evaluate drug candidates.

The company did not disclose in the cited report whether TuneLab integration includes specific assay formats, harmonized reporting templates, or internal validation steps that verify that results produced through Charles River match the platform’s required standards. It also did not state how quickly new protocols will roll out or how existing projects will be handled if they are already underway.

Investors and industry watchers may focus next on implementation details, such as whether Lilly will expand the program to additional testing partners, and how the integration affects timelines for bringing candidates into clinical trials. Another key question will be what performance or quality metrics Lilly intends to track to determine whether standardized nonclinical protocols improve decision-making over time.